9001 Background: Standard first-line therapy for EGFR mutant advanced non-small cell lung
cancer (NSCLC) is an EGFR-directed oral TKI. We evaluated whether adding pemetrexed …

BACKGROUND: Gefitinib is an effective treatment for patients with non-small cell lung
cancer who harbor activating epidermal growth factor receptor (EGFR) mutations. However …

8016 Background: Based on our promising results of phase II studies estimating gefitinib in
NSCLC pts with sensitive EGFR mutations (JCO 2006, BJC 2006), this multicenter phase III …

Most patients with non-small-cell lung cancer (NSCLC) who initially respond to epidermal
growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) eventually experience …

Background: Gefitinib and erlotinib, small-molecule kinase inhibitors that block epidermal
growth factor receptor (EGFR) signaling, have demonstrated a dramatic response rate and …

BACKGROUND: Gefitinib and erlotinib are commonly used for salvage therapy in patients
with nonsmall cell lung cancer (NSCLC) who have progressed on prior therapies. Although …

LBA7509 Background: This phase III study (V-15–32) compared gefitinib vs docetaxel on
overall survival (OS) in Japanese patients (pts) with pretreated advanced NSCLC. Methods …

PURPOSE: Gefitinib and erlotinib are potent EGFR TKIs, with antitumor activity. In this
randomized, single-center, non-comparative phase II trial, the efficacy and safety of gefitinib …

Rationale: Gefitinib is effective in treating patients with non–small cell lung cancer (NSCLC)
with epidermal growth factor receptor (EGFR) mutations. Deletions in exon 19 and L858R in …

Background Non–small-cell lung cancer with sensitive mutations of the epidermal growth
factor receptor (EGFR) is highly responsive to EGFR tyrosine kinase inhibitors such as …